alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 4,551–4,575 of 10,985 studies · free to read (page 183 of 440) · 27,380 in the whole library · How the 0–100 score works

Download bibliography of the first 500 of these studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 12,859 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Association Between Longitudinal Rate of Change in CSF Biomarkers and Subsequent Tau PET Burden in Early Braak Stages

✓ Peer-reviewed alzhub usefulness score 52 out of 100. Neurology 2026-01-28

This study investigated whether longitudinal changes in CSF AD biomarkers were associated with 18 F-MK6240 tau PET measures in early Braak stage subregions. 4 key findings →

Design: cross-sectional Participants: 78 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Low serum cholesteryl ester-docosahexaenoic acid levels in Alzheimer's disease: a case-control study

✓ Peer-reviewed alzhub usefulness score 52 out of 100. The British journal of nutrition 2003-04-01

Low n-3 polyunsaturated fatty acid (PUFA) status may be associated with neuro-degenerative disorders, in particular Alzheimer's disease, which has been associated with poor dietary fish or n-3 PUFA intake, and low docosahexaenoic acid (DHA) status. 4 key findings →

Design: case-control study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Frequency and characteristics of anxiety among patients with Alzheimer's disease and related dementias

✓ Peer-reviewed alzhub usefulness score 52 out of 100. The Journal of neuropsychiatry and clinical neurosciences 2003-01-01

The purpose of this study was to assess the cross-sectional prevalence and characteristics of anxiety among patients with Alzheimer's disease (AD), as compared with patients with frontotemporal dementia (FTD), patients with vascular dementia (VaD), and normal control subjects. 4 key findings →

Design: cross-sectional Participants: 115 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Cortical microinfarcts on 3T MRI: Clinical correlates in memory-clinic patients

✓ Peer-reviewed alzhub usefulness score 52 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2015-05-05

This is the first study to assess cerebral microinfarcts (CMIs) on 3 tesla (3T) magnetic resonance imaging (MRI) in a memory clinic population. 4 key findings →

Participants: 238 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Mini Mental State Examination and Logical Memory scores for entry into Alzheimer's disease trials

✓ Peer-reviewed alzhub usefulness score 52 out of 100. Alzheimer's research & therapy 2016-02-22

Specific cutoff scores on the Mini Mental State Examination (MMSE) and the Logical Memory (LM) test are used to determine inclusion in Alzheimer's disease (AD) clinical trials and diagnostic studies. 4 key findings →

Participants: 23,438 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Cerebral glucose metabolism and cognition in newly diagnosed Parkinson's disease: ICICLE-PD study

✓ Peer-reviewed alzhub usefulness score 52 out of 100. Journal of neurology, neurosurgery, and psychiatry 2016-10-06

FDG-PET was performed on a cohort of 79 patients with newly diagnosed PD (mean disease duration 8 months) and 20 unrelated controls. 4 key findings →

Participants: 79 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Does loneliness mediate the relation between social support and cognitive functioning in later life?

✓ Peer-reviewed alzhub usefulness score 52 out of 100. Social science & medicine (1982) 2013-09-15

Research in gerontology has demonstrated mixed effects of social support on cognitive decline and dementia: Social support has been shown to be protective in some studies, but not in others. 4 key findings →

Design: longitudinal study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

The Revised National Alzheimer's Coordinating Center's Neuropathology Form-Available Data and New Analyses

✓ Peer-reviewed alzhub usefulness score 52 out of 100. Journal of neuropathology and experimental neurology 2018-08-01

Neuropathologic evaluation remains the gold standard for determining the presence and severity of aging-related neurodegenerative diseases. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Arterial Stiffness and Long-Term Risk of Health Outcomes: The Framingham Heart Study

✓ Peer-reviewed alzhub usefulness score 52 out of 100. Hypertension (Dallas, Tex. : 1979) 2022-02-16

On long-term follow-up (median 15 years; minimum-maximum, 0-20), participants developed cardiometabolic disease (hypertension [1255 events]; diabetes [381 events]), chronic kidney disease (529 events), dementia (235 events), cardiovascular disease (684 events) a 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Medial temporal lobe subregional morphometry using high resolution MRI in Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 52 out of 100. Neurobiology of aging 2016-09-30

Autopsy studies of Alzheimer's disease (AD) have found that neurofibrillary tangle (NFT) pathology of the medial temporal lobe (MTL) demonstrates selective topography with relatively stereotyped subregional involvement at early disease stages, prompting interest in more granular measurement of these structures with in vivo magnetic resonance imaging. 4 key findings →

Participants: 86 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Cerebral microbleeds and risk of incident dementia: the Framingham Heart Study

✓ Peer-reviewed alzhub usefulness score 52 out of 100. Neurobiology of aging 2017-03-06

Cerebral microbleeds (CMBs) are MRI markers attributed to the most common cerebral angiopathies in the elderly and in patients with dementia: hypertensive and cerebral amyloid angiopathy. 4 key findings →

Participants: 85 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Radiomics: a novel feature extraction method for brain neuron degeneration disease using 18F-FDG PET imaging and its implementation for Alzheimer's disease and mild cognitive impairment

✓ Peer-reviewed alzhub usefulness score 52 out of 100. Therapeutic advances in neurological disorders 2019-03-29

Alzheimer's disease (AD) is the most common form of progressive and irreversible dementia, and accurate diagnosis of AD at its prodromal stage is clinically important. 4 key findings →

Participants: 422 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Memory, executive, and multidomain subtle cognitive impairment: clinical and biomarker findings

✓ Peer-reviewed alzhub usefulness score 52 out of 100. Neurology 2015-06-17

We studied the biomarker signatures and prognoses of 3 different subtle cognitive impairment (SCI) groups (executive, memory, and multidomain) as well as the subjective memory complaints (SMC) group. 4 key findings →

Participants: 522 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease

✓ Peer-reviewed alzhub usefulness score 52 out of 100. American journal of human genetics 2011-07-01

To identify rare causal variants in late-onset Parkinson disease (PD), we investigated an Austrian family with 16 affected individuals by exome sequencing. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled.

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed